JP7588224B2 - Ｂｃｒ－ａｂｌチロシンキナーゼの阻害のための５－及び６－アザインドール化合物 - Google Patents

Ｂｃｒ－ａｂｌチロシンキナーゼの阻害のための５－及び６－アザインドール化合物 Download PDF

Info

Publication number
JP7588224B2
JP7588224B2 JP2023521087A JP2023521087A JP7588224B2 JP 7588224 B2 JP7588224 B2 JP 7588224B2 JP 2023521087 A JP2023521087 A JP 2023521087A JP 2023521087 A JP2023521087 A JP 2023521087A JP 7588224 B2 JP7588224 B2 JP 7588224B2
Authority
JP
Japan
Prior art keywords
alkylene
compound
alkyl
independently
leukemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023521087A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023546352A5 (enExample
JP2023546352A (ja
Inventor
ジョセフ ピー． リシカトス，
サミュエル キンツ，
リー レン，
Original Assignee
エンライブン インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エンライブン インコーポレイテッド filed Critical エンライブン インコーポレイテッド
Publication of JP2023546352A publication Critical patent/JP2023546352A/ja
Priority to JP2024128215A priority Critical patent/JP2024153884A/ja
Publication of JP2023546352A5 publication Critical patent/JP2023546352A5/ja
Priority to JP2024198167A priority patent/JP2025020388A/ja
Application granted granted Critical
Publication of JP7588224B2 publication Critical patent/JP7588224B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2023521087A 2020-10-05 2021-10-04 Ｂｃｒ－ａｂｌチロシンキナーゼの阻害のための５－及び６－アザインドール化合物 Active JP7588224B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024128215A JP2024153884A (ja) 2020-10-05 2024-08-02 Ｂｃｒ－ａｂｌチロシンキナーゼの阻害のための５－及び６－アザインドール化合物
JP2024198167A JP2025020388A (ja) 2020-10-05 2024-11-13 Ｂｃｒ－ａｂｌチロシンキナーゼの阻害のための５－及び６－アザインドール化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063087763P 2020-10-05 2020-10-05
US63/087,763 2020-10-05
US202163224236P 2021-07-21 2021-07-21
US63/224,236 2021-07-21
PCT/US2021/071695 WO2022076975A1 (en) 2020-10-05 2021-10-04 5- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024128215A Division JP2024153884A (ja) 2020-10-05 2024-08-02 Ｂｃｒ－ａｂｌチロシンキナーゼの阻害のための５－及び６－アザインドール化合物

Publications (3)

Publication Number Publication Date
JP2023546352A JP2023546352A (ja) 2023-11-02
JP2023546352A5 JP2023546352A5 (enExample) 2024-08-14
JP7588224B2 true JP7588224B2 (ja) 2024-11-21

Family

ID=81125530

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2023521087A Active JP7588224B2 (ja) 2020-10-05 2021-10-04 Ｂｃｒ－ａｂｌチロシンキナーゼの阻害のための５－及び６－アザインドール化合物
JP2024128215A Withdrawn JP2024153884A (ja) 2020-10-05 2024-08-02 Ｂｃｒ－ａｂｌチロシンキナーゼの阻害のための５－及び６－アザインドール化合物
JP2024198167A Withdrawn JP2025020388A (ja) 2020-10-05 2024-11-13 Ｂｃｒ－ａｂｌチロシンキナーゼの阻害のための５－及び６－アザインドール化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024128215A Withdrawn JP2024153884A (ja) 2020-10-05 2024-08-02 Ｂｃｒ－ａｂｌチロシンキナーゼの阻害のための５－及び６－アザインドール化合物
JP2024198167A Withdrawn JP2025020388A (ja) 2020-10-05 2024-11-13 Ｂｃｒ－ａｂｌチロシンキナーゼの阻害のための５－及び６－アザインドール化合物

Country Status (10)

Country Link
US (4) US11767321B2 (enExample)
EP (1) EP4225742A4 (enExample)
JP (3) JP7588224B2 (enExample)
KR (1) KR20230104781A (enExample)
CN (1) CN119019388B (enExample)
AU (1) AU2021358123A1 (enExample)
CA (1) CA3196620A1 (enExample)
IL (1) IL301739A (enExample)
MX (1) MX2023003995A (enExample)
WO (1) WO2022076975A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024153884A (ja) * 2020-10-05 2024-10-29 エンライブン インコーポレイテッド Ｂｃｒ－ａｂｌチロシンキナーゼの阻害のための５－及び６－アザインドール化合物

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023081637A1 (en) * 2021-11-02 2023-05-11 Enliven Therapeutics, Inc. Fused tetracyclic quinazoline derivatives as inhibitors of erbb2
WO2026084735A1 (en) 2024-10-16 2026-04-23 Enliven Inc. Formulations of bcr-abl tyrosine kinase inhibitor
WO2026084950A1 (en) 2024-10-16 2026-04-23 Enliven Inc. 5- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinases for use in the treatment of cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012505916A (ja) 2008-10-16 2012-03-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 融合環ヘテロアリールキナーゼ阻害剤
JP2012517465A (ja) 2009-02-12 2012-08-02 オリバーズ・ファルマ プロテインキナーゼａｂｌおよびｓｒｃの阻害剤としてのアザインドール誘導体
JP2014502601A (ja) 2010-12-17 2014-02-03 エフ．ホフマン−ラ ロシュ アーゲー 置換６，６−縮合窒素複素環化合物及びその使用
JP2016507508A (ja) 2012-12-28 2016-03-10 オリバーズ・ファルマ マルチキナーゼ阻害薬としてのアザインドール誘導体

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU742999B2 (en) 1997-08-20 2002-01-17 Warner-Lambert Company Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
US6253076B1 (en) 1999-02-25 2001-06-26 Ericsson Inc. Manufacturing method for wireless communications devices employing potentially different versions of integrated circuits
EP1161431A4 (en) 1999-03-10 2002-04-24 Merck & Co Inc 6-AZAINDOL COMPOUNDS AS AN ANTAGONISTS OF THE GONADOTROPIN RELEASE HORMONES
AU3396000A (en) 1999-03-10 2000-09-28 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
AU1053501A (en) 1999-11-02 2001-05-14 Ajinomoto Co., Inc. Polyazanaphthalene compound and medicinal use thereof
US20030187261A1 (en) 2000-01-07 2003-10-02 Libor Havlicek Purine derivatives, process for their preparation and use thereof
US20020061892A1 (en) 2000-02-22 2002-05-23 Tao Wang Antiviral azaindole derivatives
US6469026B2 (en) 2000-03-24 2002-10-22 Millennium Pharmaceuticals, Inc. Isoquinolone inhibitors of factor Xa
US6548517B2 (en) 2000-03-24 2003-04-15 Millennium Pharmaceuticals, Inc. Oxindole inhibitors of factor Xa
US20030186972A1 (en) 2001-03-26 2003-10-02 Millennium Pharmaceuticals, Inc. Isoquinolone inhibitors of factor Xa
JP4451136B2 (ja) 2002-04-08 2010-04-14 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性阻害薬
CA2485641C (en) 2002-06-06 2010-12-14 Eisai Co., Ltd. Novel condensed imidazole derivatives
CA2492607A1 (en) 2002-07-25 2004-02-05 Micrologix Biotech Inc. Anti-viral 7-deaza d-nucleosides and uses thereof
EP2573079A3 (en) * 2002-08-23 2015-03-11 Novartis AG Benzimidazole quinolinones and uses thereof
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
NZ538936A (en) 2002-09-26 2006-12-22 Eisai Co Ltd Combination drug comprising a combination of a dipeptidyl peptidase IV (DPPIV) inhibitor with biguanide
WO2005013950A2 (en) 2003-08-08 2005-02-17 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
JP2007503388A (ja) 2003-08-22 2007-02-22 アバニール・ファーマシューティカルズ マクロファージ遊走阻止因子の阻害剤としての置換ナフチリジン誘導体、およびヒト疾患の治療におけるそれらの使用
WO2005053695A1 (ja) 2003-12-04 2005-06-16 Eisai Co., Ltd. 多発性硬化症予防剤または治療剤
JP2007513955A (ja) 2003-12-09 2007-05-31 バーテックス　ファーマシューティカルズ　インコーポレイテッド ナフチリジン誘導体およびそれらのムスカリン受容体の調節剤としての使用
GB0330043D0 (en) * 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
WO2005063720A1 (ja) * 2003-12-25 2005-07-14 Nippon Shinyaku Co., Ltd. アミド誘導体及び医薬
EP2325184A1 (en) 2004-06-30 2011-05-25 Vertex Pharmceuticals Incorporated Azaindoles useful as inhibitors of protein kinases
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
WO2006128172A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating b cell regulated autoimmune disorders
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
GB0520958D0 (en) * 2005-10-14 2005-11-23 Cyclacel Ltd Compound
KR20080092412A (ko) 2006-02-06 2008-10-15 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물 및 조성물
EP2010530A2 (en) 2006-03-23 2009-01-07 Novartis AG Methods for the preparation of imidazole-containing compounds
WO2007125405A2 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
JP2009537520A (ja) 2006-05-15 2009-10-29 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｆｇｆ受容体キナーゼ阻害剤のための組成物および方法
DE602006004196D1 (de) 2006-06-01 2009-01-22 Cellzome Ag Verfahren zur Identifizierung von mit ZAP-70 wechselwirkenden Molekülen und zur ZAP-70-Reinigung
BRPI0713187A2 (pt) 2006-07-20 2012-10-16 Mehmet Kahraman método de inibir rho-quinase, método de tratamento de doença mediada por rho-quinase, composto e composição farmacêutica
US7897762B2 (en) 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
AU2007305016B2 (en) 2006-10-02 2011-11-03 Novartis Ag Compounds and compositions as protein kinase inhibitors
EP1914234A1 (en) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
DK2094702T3 (en) 2006-12-14 2015-12-07 Gilead Sciences Inc viral inhibitors
CN101842098A (zh) 2007-08-10 2010-09-22 基因实验室技术有限公司 用于治疗病毒感染的含氮的二环化学实体
US20110160232A1 (en) 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
US20110098267A1 (en) 2008-02-07 2011-04-28 Synta Pharmaceuticals Corporation Topical formulations for the treatment of psoriasis
WO2009146034A2 (en) 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
KR20120049852A (ko) 2009-06-30 2012-05-17 시가 테크놀로지스, 인크. 뎅기 바이러스 감염의 치료 및 예방
DE102009033208A1 (de) 2009-07-15 2011-01-20 Merck Patent Gmbh Aminopyridinderivate
ES2749504T3 (es) 2009-10-13 2020-03-20 Ligand Pharm Inc Compuestos de moléculas pequeñas miméticos del factor de crecimiento hematopoyético y sus usos
SMT201700581T1 (it) 2009-12-21 2018-01-11 Samumed Llc 1h-pirazolo[3,4-b]piridine e loro usi terapeutici
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
WO2012068406A2 (en) 2010-11-18 2012-05-24 Ligand Pharmaceuticals Incorporated Use of hematopoietic growth factor mimetics
JP5990106B2 (ja) 2011-01-28 2016-09-07 佐藤製薬株式会社 縮環化合物
WO2012154888A1 (en) 2011-05-09 2012-11-15 Proteostasis Therapeutics, Inc. Compounds for treating protein folding disorders
JP2014515368A (ja) * 2011-05-26 2014-06-30 第一三共株式会社 プロテインキナーゼ阻害剤としての複素環化合物
EP2570125A1 (en) 2011-09-16 2013-03-20 Almirall, S.A. Ep1 receptor ligands
WO2013078254A1 (en) 2011-11-22 2013-05-30 Array Biopharma Inc. Bicyclic heteroaryl derivatives as kinase inhibitors
DE102011121022A1 (de) 2011-12-13 2013-06-13 Merck Patent Gmbh Organische Sensibilisatoren für Up- Conversion
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
CA2883386A1 (en) 2012-09-14 2014-03-20 Eternity Bioscience Inc. Aminoisoquinoline derivatives as protein kinase inhibitors
EP2818472A1 (en) 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Imidazo[4,5-c]pyridine and pyrrolo[3,2-c]pyridine compounds as G-protein-coupled receptor kinase 5 (GRK5) modulators
US10471139B2 (en) 2013-08-15 2019-11-12 The University Of Kansas Toll-like receptor agonists
TWI652014B (zh) 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
ES2919024T3 (es) 2014-02-11 2022-07-21 Mitokinin Inc Composiciones y procedimientos que utilizan las mismas para el tratamiento de enfermedades neurodegenerativas y mitocondriales
EP3140274A1 (en) 2014-05-09 2017-03-15 Sloan-kettering Institute For Cancer Research Naphthaquinone methyltransferase inhibitors and uses thereof
GB201410815D0 (en) 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
US20150376219A1 (en) 2014-06-30 2015-12-31 Minghong Zhong Selective Preparations of Purine Nucleosides and Nucleotides: Reagents and Methods
JP2017522324A (ja) 2014-07-17 2017-08-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 新規ナフチリジン及びイソキノリンならびにｃｄｋ８／１９阻害剤としてのその使用
WO2016014674A1 (en) 2014-07-22 2016-01-28 University Of Maryland, College Park Linked diaryl compounds with anticancer properties and methods of using the same
WO2016144706A2 (en) 2015-03-11 2016-09-15 Pharmakea, Inc. Autotaxin inhibitor compounds and uses thereof
CN107635984B (zh) 2015-03-11 2021-04-13 Fmc公司 杂环取代的二环唑杀有害生物剂
CN107922389A (zh) 2015-06-17 2018-04-17 拜耳制药股份公司 3‑氨基‑1,5,6,7‑四氢‑4h‑吲哚‑4‑酮
EP3322409A4 (en) 2015-07-15 2019-07-24 Aurigene Discovery Technologies Limited SUBSTITUTED AZA COMPOUNDS AS IRAQ-4 INHIBITORS
US10308629B2 (en) 2015-08-05 2019-06-04 Bayer Pharma Aktiengesellschaft 1H-pyrrol-3-amines
WO2017031427A1 (en) 2015-08-19 2017-02-23 3-V Biosciences, Inc. COMPOUNDS AND METHODS FOR INHIBITING mTOR
US10696687B2 (en) 2015-08-20 2020-06-30 Changzhou Jiekai Pharmatech Co., Ltd. Pyrazolo fused heterocyclic compounds as ERK inhibitors
EP3350198A4 (en) 2015-09-18 2019-04-03 The Scripps Research Institute RNA-FOCUSED SMALL MOLECULES TO INHIBIT RNA TOXICITY IN MYOTONIC DYSTROPHY
MD3377488T2 (ro) 2015-11-19 2023-02-28 Incyte Corp Compuși heterociclici ca imunomodulatori
GB201521059D0 (en) 2015-11-30 2016-01-13 Isis Innovation Inhibitors of metallo-beta-lactamases
WO2017094750A1 (ja) 2015-12-01 2017-06-08 日本農薬株式会社 ３ｈ‐ピロロピリジン化合物若しくはそのｎ‐オキサイド、又はそれらの塩類及び該化合物を含有する農園芸用殺虫剤並びにその使用方法
HRP20221051T8 (hr) 2016-04-15 2023-07-21 Cancer Research Technology Limited Heterociklički spojevi kao inhibitori ret kinaze
KR102706837B1 (ko) 2016-04-15 2024-09-19 캔써 리서치 테크놀로지 리미티드 Ret 키나아제 억제제로서의 헤테로사이클릭 화합물
WO2019000683A1 (zh) 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
JP7311228B2 (ja) 2017-06-30 2023-07-19 ベイジン タイド ファーマシューティカル カンパニー リミテッド Ｒｈｏ－関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用
US10329282B2 (en) 2017-06-30 2019-06-25 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
CN109721620B (zh) 2017-10-27 2022-05-13 药捷安康(南京)科技股份有限公司 Hpk1抑制剂及其用途
WO2019113523A1 (en) 2017-12-08 2019-06-13 Ashok Bajji Compounds and therapeutic uses thereof
EP3728253B1 (en) 2017-12-19 2024-03-27 Bristol-Myers Squibb Company 6-azaindole compounds
CN112105610B (zh) 2018-03-13 2024-01-26 朱比连特普罗德尔有限责任公司 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物
TW202003430A (zh) 2018-03-28 2020-01-16 美商佩樂敦治療公司 以ＨＩＦ-２-α之抑制劑降低消化系統發炎之方法
CN112154626B (zh) 2018-05-14 2024-08-23 区块链控股有限公司 使用区块链执行原子交换的计算机实现的系统和方法
WO2020021024A1 (en) 2018-07-26 2020-01-30 Phenex Pharmaceuticals Ag Substituted bicyclic compounds as modulators of the aryl hydrocarbon receptor (ahr)
CN117186092A (zh) 2018-11-07 2023-12-08 四川科伦博泰生物医药股份有限公司 并环化合物、其制备方法及用途
TW202039483A (zh) 2018-11-22 2020-11-01 英屬開曼群島商百濟神州有限公司 作為HPK1抑制劑的吡咯並[2,3-b]吡啶以及它們的用途
WO2020181050A1 (en) 2019-03-05 2020-09-10 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
KR20220050126A (ko) 2019-06-12 2022-04-22 티엠이엠16에이 리미티드 호흡기 질환을 치료하기 위한 화합물
US12703697B2 (en) 2019-07-09 2026-08-11 Icagen, Llc BCAT modulation
US12459958B2 (en) 2019-07-17 2025-11-04 Beone Medicines I Gmbh Tricyclic compounds as HPK1 inhibitor and the use thereof
CN116789681B (zh) 2019-08-09 2025-09-12 四川科伦博泰生物医药股份有限公司 含有并环基团的咪唑并嘧啶类化合物、其制备方法及用途
CR20220178A (es) 2019-10-25 2022-06-15 Gilead Sciences Inc Compuestos moduladores de glp-1r
CA3196620A1 (en) 2020-10-05 2022-04-14 Enliven Therapeutics, Inc. 5- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinases
WO2022076973A1 (en) 2020-10-05 2022-04-14 Enliven Therapeutics, Inc. 7-azaindole compounds for inhibition of bcr-abl tyrosine kinases
EP4256751A1 (en) 2020-12-02 2023-10-11 Trock, Stanislav Blockchain
WO2022146920A1 (en) * 2020-12-28 2022-07-07 Celgene Corporation Heterocyclic compounds and their use for parasitic diseases
US20240287062A1 (en) 2021-05-07 2024-08-29 Enliven Inc. Naphthyridone compounds for inhibition of raf kinases and/or bcr-abl tyrosine kinases
GB2611325A (en) 2021-09-30 2023-04-05 Nchain Licensing Ag Propagating locking scripts
WO2024098001A1 (en) 2022-11-04 2024-05-10 Enliven Inc. Naphthyridone compounds for inhibition of raf kinases
WO2024097953A1 (en) 2022-11-04 2024-05-10 Enliven Inc. Naphthyridine compounds for inhibition of raf kinases
WO2024159094A1 (en) 2023-01-27 2024-08-02 Enliven Inc. Pyrimidinyl (hetero)aromatic aminopyridine compounds for inhibition of raf kinases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012505916A (ja) 2008-10-16 2012-03-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 融合環ヘテロアリールキナーゼ阻害剤
JP2012517465A (ja) 2009-02-12 2012-08-02 オリバーズ・ファルマ プロテインキナーゼａｂｌおよびｓｒｃの阻害剤としてのアザインドール誘導体
JP2014502601A (ja) 2010-12-17 2014-02-03 エフ．ホフマン−ラ ロシュ アーゲー 置換６，６−縮合窒素複素環化合物及びその使用
JP2016507508A (ja) 2012-12-28 2016-03-10 オリバーズ・ファルマ マルチキナーゼ阻害薬としてのアザインドール誘導体

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024153884A (ja) * 2020-10-05 2024-10-29 エンライブン インコーポレイテッド Ｂｃｒ－ａｂｌチロシンキナーゼの阻害のための５－及び６－アザインドール化合物

Also Published As

Publication number Publication date
AU2021358123A1 (en) 2023-06-08
JP2024153884A (ja) 2024-10-29
US20230065635A1 (en) 2023-03-02
CN119019388A (zh) 2024-11-26
CN119019388B (zh) 2025-09-12
KR20230104781A (ko) 2023-07-10
US20250236621A1 (en) 2025-07-24
US20230382907A1 (en) 2023-11-30
CA3196620A1 (en) 2022-04-14
AU2021358123A9 (en) 2024-07-25
US11807638B2 (en) 2023-11-07
JP2023546352A (ja) 2023-11-02
JP2025020388A (ja) 2025-02-12
MX2023003995A (es) 2023-06-12
WO2022076975A1 (en) 2022-04-14
US12240846B2 (en) 2025-03-04
US20230130724A1 (en) 2023-04-27
EP4225742A4 (en) 2024-11-06
IL301739A (en) 2023-05-01
EP4225742A1 (en) 2023-08-16
US11767321B2 (en) 2023-09-26

Similar Documents

Publication Publication Date Title
US11623921B2 (en) Indole carboxamide compounds
US11807638B2 (en) 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases
RU2606497C2 (ru) Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ
JP7826325B2 (ja) Ｂｃｒ－ａｂｌチロシンキナーゼの阻害のための７－アザインドール化合物
US12060365B2 (en) Cycloalkane-1,3-diamine derivative
TW201838981A (zh) 嘧啶基-吡啶氧基-萘基化合物以及治療ire1相關之疾病及病症的方法
WO2022236319A1 (en) Naphthyridone compounds for inhibition of raf kinases and/or bcr-abl tyrosine kinases
US11970474B2 (en) Substituted benzodiazoles and use thereof in therapy
CN116648453A (zh) 用于抑制Bcr-Abl酪氨酸激酶的5-和6-氮杂吲哚化合物
WO2026084950A1 (en) 5- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinases for use in the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240802

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240802

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240802

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241022

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241031

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241111

R150 Certificate of patent or registration of utility model

Ref document number: 7588224

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350